Patient stories
FILTER BY TESTS
Melanoma diagnosis, now what?
Melanoma is one of the most common cancers found among adults, aged 15-29, in the U.S. and the deadliest if not caught early. There are emerging technologies to help identify a patient’s risk for recurrence and metastasis such as gene expression profiling. Learn about DecisionDX-Melanoma, which is a predictive test to help patients make the most informed treatment decisions.
From Fear to Confidence: DecisionDx-Melanoma. Greg’s Story of Empowerment Over a Melanoma Diagnosis
Discover Greg’s inspiring journey from a cancer diagnosis to a life of outdoor adventures, empowered by the DecisionDx-Melanoma test. Follow his path to knowledge and resilience in the face of melanoma.
Don't let fear define your journey: a uveal melanoma patient journey
Danet didn’t let fear of the unknown define her uveal melanoma journey. Hear how Castle Biosciences DecisionDx-UM test impacted her treatment.
Be your own advocate: Morgan England, Stage III melanoma survivor, shares her story
As a Stage III Melanoma survivor, Morgan speaks on how important it is to be your own advocate. After her diagnosis, she requested the DecisionDx-Melanoma test from her doctor for the additional information it can provide. The results she received from her DecisionDx-Melanoma test report continue to help reduce her anxiety and provide confidence about her future.
Jerry W. – A Second Chance for Jerry
He just knew he was going to die. In September 2009, Jerry W., a retired GM employee, was diagnosed with uveal melanoma. His entire world collapsed.
Peter L. – The Test of Time
It was just two days before the radiation treatment of his uveal melanoma, or eye cancer.
Mary D. – Taking Matters Into Her Own Hands
Mary sat in disbelief. How could that small dot in her eye, the one her doctor had called a “freckle” just twelve years ago, now be a malignant tumor?
Mary F. – Marking “Cancerversaries”
Since her diagnosis with uveal melanoma in September 2013, life looks very different for Mary Judy French.
A life-changing prognosis of uveal melanoma: Kevin’s story
After being diagnosed with uveal (or ocular) melanoma, Kevin was directed to explore the benefits and indications of Castle Biosciences' DecisionDx-UM gene expression profile (GEP) test, which predicts a patient’s risk based upon their tumor’s own unique biology. The findings of the test, Kevin says, "were of huge importance to myself and my family. They put me at rest and we could all move on. The Castle's uveal melanoma prognostic platform can truly be life-changing."